Novel Binding Mode of a Potent and Selective Tankyrase Inhibitor

被引:56
|
作者
Gunaydin, Hakan [1 ]
Gu, Yan [1 ]
Huang, Xin [1 ]
机构
[1] Amgen Inc, Dept Mol Struct, Cambridge, MA 02142 USA
来源
PLOS ONE | 2012年 / 7卷 / 03期
关键词
POLY(ADP-RIBOSE) POLYMERASE; STI-571; INHIBITION; CATALYTIC DOMAIN; STRUCTURAL BASIS; TYROSINE KINASE; MOLECULE; CANCER;
D O I
10.1371/journal.pone.0033740
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tankyrases (TNKS1 and TNKS2) are key regulators of cellular processes such as telomere pathway and Wnt signaling. IWRs (inhibitors of Wnt response) have recently been identified as potent and selective inhibitors of tankyrases. However, it is not clear how these IWRs interact with tankyrases. Here we report the crystal structure of the catalytic domain of human TNKS1 in complex with IWR2, which reveals a novel binding site for tankyrase inhibitors. The TNKS1/IWR2 complex provides a molecular basis for their strong and specific interactions and suggests clues for further development of tankyrase inhibitors.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Discovery of Novel, Induced-Pocket Binding Oxazolidinones as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors
    Bregman, Howard
    Chakka, Nagasree
    Guzman-Perez, Angel
    Gunaydin, Hakan
    Gu, Yan
    Huang, Xin
    Berry, Virginia
    Liu, Jingzhou
    Teffera, Yohannes
    Huang, Liyue
    Egge, Bryan
    Mullady, Erin L.
    Schneider, Steve
    Andrews, Paul S.
    Mishra, Ankita
    Newcomb, John
    Serafino, Randy
    Strathdee, Craig A.
    Turci, Susan M.
    Wilson, Cindy
    DiMauro, Erin F.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (11) : 4320 - 4342
  • [2] Development of Novel Dual Binders as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors
    Hua, Zihao
    Bregman, Howard
    Buchanan, John L.
    Chakka, Nagasree
    Guzman-Perez, Angel
    Gunaydin, Hakan
    Huang, Xin
    Gu, Yan
    Berry, Virginia
    Liu, Jingzhou
    Teffera, Yohannes
    Huang, Liyue
    Egge, Bryan
    Emkey, Renee
    Mullady, Erin L.
    Schneider, Steve
    Andrews, Paul S.
    Acquaviva, Lisa
    Dovey, Jennifer
    Mishra, Ankita
    Newcomb, John
    Saffran, Douglas
    Serafino, Randy
    Strathdee, Craig A.
    Turci, Susan M.
    Stanton, Mary
    Wilson, Cindy
    DiMauro, Erin F.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (24) : 10003 - 10015
  • [3] Discovery of a selective c-MET inhibitor with a novel binding mode
    Collie, Gavin W.
    Barlind, Louise
    Bazzaz, Sana
    Borjesson, Ulf
    Dale, Ian L.
    Disch, Jeremy S.
    Habeshian, Sevan
    Jetson, Rachael
    Khurana, Puneet
    Madin, Andrew
    Michaelides, Iacovos N.
    Peng, Ling
    Snijder, Arjan
    Stubbs, Christopher J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 75
  • [4] Identification of novel, potent and selective inhibitor of VRAC
    Jeon, Dong-Kyu
    Namkung, Wan
    FASEB JOURNAL, 2019, 33
  • [5] Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
    Hu, Chen
    Wang, Aoli
    Wu, Hong
    Qi, Ziping
    Li, Xixiang
    Yan, Xiao-E
    Chen, Cheng
    Yu, Kailin
    Zou, Fengming
    Wang, Wenchao
    Wang, Wei
    Wu, Jiaxin
    Liu, Juan
    Wang, Beilei
    Wang, Li
    Ren, Tao
    Zhang, Shanchun
    Yun, Cai-Hong
    Liu, Jing
    Liu, Qingsong
    ONCOTARGET, 2017, 8 (11) : 18359 - 18372
  • [6] Use of structure efficiency relationships to generate NVP-TNKS656, an orally active, highly potent and selective tankyrase inhibitor with enthalpy driven binding
    Shultz, Michael D.
    Cheung, Atwood K.
    Chen, Zhouliang
    Chin, Donovan N.
    Toure, Barry
    Visser, Michael
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [7] Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics
    Nkizinkiko, Yves
    Kumar, B. V. S. Suneel
    Jeankumar, Variam Ullas
    Haikarainen, Teemu
    Koivunen, Jarkko
    Madhuri, Chanduri
    Yogeeswari, Perumal
    Venkannagari, Harikanth
    Obaji, Ezeogo
    Pihlajaniemi, Taina
    Sriram, Dharmarajan
    Lehtio, Lari
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (15) : 4139 - 4149
  • [8] Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode
    Down, Kenneth
    Amour, Augustin
    Anderson, Niall A.
    Barton, Nick
    Campos, Sebastien
    Cannons, Edward P.
    Clissold, Cole
    Convery, Maire A.
    Coward, John J.
    Doyle, Kevin
    Duempelfeld, Birgit
    Edwards, Christopher D.
    Goldsmith, Michael D.
    Krause, Jana
    Mallett, David N.
    McGonagle, Grant A.
    Patel, Vipulkumar K.
    Rowedder, James
    Rowland, Paul
    Sharpe, Andrew
    Sriskantharajah, Srividya
    Thomas, Daniel A.
    Thomson, Douglas W.
    Uddin, Sorif
    Hamblin, J. Nicole
    Hessel, Edith M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (18) : 13780 - 13792
  • [9] Development of a novel, selective, and potent inhibitor of RON kinase
    Kaadige, Mohan Rao
    Thode, Trason
    Fornetti, Jaime
    Weston, Alexis
    Ng, Serina
    Ghosh-Halder, Tithi
    Bargenquast, Taylor
    Durbin, Brian
    Kasibhatla, Srinivas
    Soldi, Raffaella
    Welm, Alana
    Sharma, Sunil
    CANCER RESEARCH, 2024, 84 (06)
  • [10] Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor
    Ryu, Hwani
    Nam, Ky-Youb
    Kim, Hyo Jeong
    Song, Jie-Young
    Hwang, Sang-Gu
    Kim, Jae Sung
    Kim, Joon
    Ahn, Jiyeon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (14)